Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy... Show more
EKTAY broke above its upper Bollinger Band on August 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In of the 40 cases the stock fell afterwards. This puts the odds of success at .
The 10-day RSI Indicator for EKTAY moved out of overbought territory on August 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where EKTAY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on August 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EKTAY as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
EKTAY moved below its 50-day moving average on August 28, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EKTAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for EKTAY entered a downward trend on August 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Moving Average Convergence Divergence (MACD) for EKTAY just turned positive on August 13, 2025. Looking at past instances where EKTAY's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for EKTAY crossed bullishly above the 50-day moving average on August 25, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EKTAY advanced for three days, in of 302 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.982) is normal, around the industry mean (60.367). P/E Ratio (65.213) is within average values for comparable stocks, (38.496). Projected Growth (PEG Ratio) (1.293) is also within normal values, averaging (1.728). EKTAY's Dividend Yield (0.048) is considerably higher than the industry average of (0.019). P/S Ratio (1.006) is also within normal values, averaging (80.347).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EKTAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EKTAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Industry MedicalNursingServices
A.I.dvisor tells us that EKTAY and SAUHY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EKTAY and SAUHY's prices will move in lockstep.
Ticker / NAME | Correlation To EKTAY | 1D Price Change % | ||
---|---|---|---|---|
EKTAY | 100% | -4.30% | ||
SAUHY - EKTAY | 31% Poorly correlated | +0.68% | ||
SMMNY - EKTAY | 29% Poorly correlated | +0.84% | ||
PHG - EKTAY | 29% Poorly correlated | -0.40% | ||
GNGBY - EKTAY | 26% Poorly correlated | +0.65% | ||
NEOG - EKTAY | 26% Poorly correlated | +0.17% | ||
More |
Ticker / NAME | Correlation To EKTAY | 1D Price Change % |
---|---|---|
EKTAY | 100% | -4.30% |
Medical/Nursing Services industry (225 stocks) | 22% Poorly correlated | +0.26% |
Health Services industry (435 stocks) | 18% Poorly correlated | +0.00% |